Researchers collected admission and discharge nasal swabs from patients, totaling more than 27,000 specimens, using three different commercial real-time polymerase chain reaction MRSA tests. The researchers found the performance of the three commercial tests were fairly similar.
Given the similar performance of all three tests, the researchers suggest healthcare providers consider the cost of the MRSA tests as well as the specificity of the test’s results to determine which would be best for the hospital’s specific surveillance program.
More articles on MRSA:
Tapeworm drug effectively treats MRSA in lab study
Former NFL player sues team over MRSA infection
Cigarette smoke makes MRSA more aggressive, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
